Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609580 · ClinicalTrials.gov registry record · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
A Phase 1 study of Urinary Retention, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 1
- Study location
NCT03609580: Recruiting Phase 1 study of Urinary Retention, sponsored by Hackensack Meridian Health.
NCT03609580 is a Phase 1 study of Urinary Retention that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 127 participants, roughly in line with the 129-participant average among 11 other Urinary Retention trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03609580, a Phase 1 study of Urinary Retention, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 1
- Study location
Study Summary
Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest. Urinary retention is uncomfortable, increases anxiety, increases hospital length of stay, and leads to more procedures such as putting in a bladder catheter (Foley). This is uncomfortable, and can lead to bleeding, infection, damage to the urethra and/or bladder and bladder spasm. The goal of this study is to attempt to prevent inability to urinate by giving patients a medication called Flomax (Tamusolin) every day beginning a week before surgery. That medication relaxes the prostate. It's approved by the Food and Drug Administration (FDA) to improve urinary flow in those with enlarged prostates. It is also commonly used in patients with bladder problems due to inability to urinate who have required a Foley.
Primary Outcome
The absence of voiding naturally after undergoing thoracic surgery needing an intervention as a Foley catheter or a catheterization. Documentation for first void, Post bladder scan showing more that 300cc of residual urine in the bladder (failure to urinate), or following spontaneous urination if there is more than 300cc of residual urine in the bladder (inadequate urination)
Conditions Studied
Interventions
- DRUG Tamsulosin - 1 week
- DRUG Tamsulosin - 3 days
Study Locations (1)
New Jersey
- Daniel Mansour - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
What NCT03609580 shows while recruiting
NCT03609580 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 129-participant average among 11 other Urinary Retention trials with a reported enrollment target.
The record links to 1 condition, with Urinary Retention appearing as the primary indexed condition, and to 2 interventions - of which Tamsulosin - 1 week is the first listed.
NCT03609580 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03609580 about?
NCT03609580 is a clinical study titled "Post-operative Urinary Retention (POUR) Following Thoracic Surgery". Inability to urinate a common complication that happens to many patients after a surgery, especially in men over 60 years of age who undergo surgery on their chest. Urinary retention is uncomfortable, increases anxiety, increases hospital length of stay, and leads to more procedures such as putting ...
What is the current status of trial NCT03609580?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2018-05-07. Estimated completion is 2026-03-30.
What conditions does trial NCT03609580 study?
This clinical trial studies the following conditions: Urinary Retention.
What interventions are being tested in trial NCT03609580?
The interventions under investigation include: Tamsulosin - 1 week (DRUG), Tamsulosin - 3 days (DRUG).
Who is sponsoring clinical trial NCT03609580?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03609580 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Retention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03609580's enrollment target sits among peer trials
127 3rd of 11 higher than 9 of 11 other Urinary Retention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Retention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
RECRUITING · Early Phase 1
-
Comparison of Urinary Flow Study
RECRUITING · NA
-
Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
RECRUITING · NA
-
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
RECRUITING · NA
-
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
RECRUITING · NA
-
Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI